Renishaw’s novel drug delivery system, to be used in partnership with Herantis Pharma Plc’s drug candidate CDNF for the treatment of Parkinson’s disease, is about to enter phase 1-2 clinical trials. The study will be supported by a €6 million grant from Horizon 2020, the European Union’s Framework Programme for Research and Innovation.
Neurodegenerative diseases such as Parkinson’s are notoriously difficult to target with medication due to the protective role of the blood-brain barrier. Working in partnership with leading neurosurgeons, Renishaw has developed an innovative system which bypasses the blood-brain barrier, delivering pharmaceuticals directly into the brain tissue.
